Targeted combo tested for tough breast cancer
NCT ID NCT04216472
Summary
This study tested whether adding a targeted drug called alpelisib to a chemotherapy drug (nab-paclitaxel) could help shrink tumors before surgery. It was for people with a specific, hard-to-treat type of breast cancer (triple-negative) that had not responded well to a common first-line chemotherapy. The goal was to see if this combination could improve the chance of having little or no cancer left at surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.